Hemogenyx Pharmaceuticals said it had filed a patent covering new methods to transplant bone marrow and treat blood cancers. The new patent covered a method of application of bi-specific antibodies (CDX) for conditioning patients for bone marrow transplantation and composition matter (sequences) of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells/hematopoietic progenitors and a number of leukemias, such as acute myeloid leukemia, the company said. The antibody being developed, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and had the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor,' the company said. 'Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,' it added.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.